Discussion of preliminary results from an ongoing phase 1 clinical trial studying the safety and efficacy of novel BCL2 inhibitor BGB-11417 alone and in combination with the next-generation BTK inhibitor zanubrutinib.
Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
One click to our most popular content.